Skip to content

Study · Animal study (in vivo) · 2014

5 results

Rapidly dissolvable microneedle patches for transdermal delivery of exenatide.

Zhu Z, Luo H, Lu W, Luan H, Wu Y, Luo J, Wang Y, Pi J, Lim CY, Wang H

Pharmaceutical research28 May 2014Cited by 92 (Europe PMC)

PMID24867426 (opens in a new tab)DOI10.1007/s11095-014-1424-1 (opens in a new tab)PepBankPUB-24867426
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the animal delivery study, exenatide microneedles showed antidiabetic efficacy comparable to subcutaneous injection.

    In plain wordsIn animals, exenatide needles had diabetes effects comparable to subcutaneous exenatide injections.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAntidiabetic efficacy
    Study

    n: not reported in source

    Comparator
    Subcutaneous exenatide injection
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · transdermalAs given in this study.

    Source sentences

    Summary
    Transdermal pharmacokinetics and antidiabetic effects studies demonstrated that fabricated EXT MNs induced comparable efficacy to SC injection.

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 02AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Safety outcome

    After exenatide microneedle disruption, skin barrier properties recovered within 10-12 h in the delivery study.

    In plain wordsIn animals, the skin barrier recovered within 10-12 h after needle application.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSkin barrier recovery
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    Additionally, transepidermal water loss (TEWL) determinations showed that skin's barrier properties disrupted by MNs recovered within 10-12 h.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 03LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Other

    In laboratory tests, exenatide-loaded hyaluronate microneedles had sufficient strength, which could decrease with higher water content.

    In plain wordsIn lab tests, exenatide-loaded needles had sufficient strength, which could decrease as water content increased.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMicroneedle strength
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    EXT-loaded dissolving MNs made of HA possessed sufficient mechanical strength and the strength could be weakened as the water content increases.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 04LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Activity measurement

    Exenatide retained pharmacological activity during microneedle fabrication and one-month storage.

    In plain wordsIn lab tests, exenatide retained activity during needle production and one-month storage.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeActivity preservation
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    The EXT preserved its pharmacological activity during fabrication and one-month storage.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 05LabNot a test of Exenatide (exendin-4) aloneOther designOther

    In vitro and in vivo tests showed skin penetration and dissolution of exenatide microneedles within 2 min.

    In plain wordsIn lab and animal tests, exenatide needles entered skin and dissolved within 2 min.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSkin insertion and drug release
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Skin and wound

    Source sentences

    Summary
    With the aid of spring-operated applicator, dissolving MNs could be readily penetrated into the skin in vitro/in vivo, and then rapidly dissolved to release encapsulated drug within 2 min.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.